X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse SHASUN PHARMA with MYLAN INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs MYLAN (US) - Comparison Results

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 SHASUN PHARMA   MYLAN
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
MYLAN
Dec-14
SHASUN PHARMA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs943,805-   
Low Rs462,682-   
Sales per share (Unadj.) Rs214.21,302.8-  
Earnings per share (Unadj.) Rs5.3156.9-  
Cash flow per share (Unadj.) Rs15.8252.6-  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %1.40-  
Book value per share (Unadj.) Rs53.3647.6-  
Shares outstanding (eoy) m56.62378.37-   
Bonus/Rights/Conversions -OI-  
Price / Sales ratio x0.32.5 13.1%   
Avg P/E ratio x13.120.7 63.4%  
P/CF ratio (eoy) x4.412.8 34.4%  
Price / Book Value ratio x1.35.0 26.2%  
Dividend payout %18.70-   
Avg Mkt Cap Rs m3,9581,227,273 0.3%   
No. of employees `000NA25.0 0.0%   
Total wages/salary Rs m2,1640-   
Avg. sales/employee Rs ThNM19,716.9-  
Avg. wages/employee Rs ThNM0-  
Avg. net profit/employee Rs ThNM2,375.2-  
INCOME DATA
Net Sales Rs m12,127492,922 2.5%  
Other income Rs m229-2,873 -8.0%   
Total revenues Rs m12,356490,049 2.5%   
Gross profit Rs m1,009122,592 0.8%  
Depreciation Rs m59436,203 1.6%   
Interest Rs m41521,262 2.0%   
Profit before tax Rs m23062,254 0.4%   
Minority Interest Rs m0-255 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-732,618 -2.8%   
Profit after tax Rs m30259,381 0.5%  
Gross profit margin %8.324.9 33.5%  
Effective tax rate %-31.74.2 -752.9%   
Net profit margin %2.512.0 20.7%  
BALANCE SHEET DATA
Current assets Rs m6,884433,344 1.6%   
Current liabilities Rs m8,456338,788 2.5%   
Net working cap to sales %-13.019.2 -67.6%  
Current ratio x0.81.3 63.6%  
Inventory Days Days6278 78.9%  
Debtors Days Days108107 100.3%  
Net fixed assets Rs m4,970114,036 4.4%   
Share capital Rs m11317,431 0.6%   
"Free" reserves Rs m2,8750-   
Net worth Rs m3,020245,031 1.2%   
Long term debt Rs m1,817366,052 0.5%   
Total assets Rs m13,347986,961 1.4%  
Interest coverage x1.63.9 39.5%   
Debt to equity ratio x0.61.5 40.3%  
Sales to assets ratio x0.90.5 181.9%   
Return on assets %5.48.2 65.8%  
Return on equity %10.024.2 41.3%  
Return on capital %13.313.6 97.8%  
Exports to sales %46.40-   
Imports to sales %14.20-   
Net fx Rs m3,6690-   
CASH FLOW
From Operations Rs m39864,795 0.6%  
From Investments Rs m-1,635-51,099 3.2%  
From Financial Activity Rs m1,309-17,073 -7.7%  
Net Cashflow Rs m71-3,378 -2.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 63.85 Rs / USD

Compare SHASUN PHARMA With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare SHASUN PHARMA With: ALKEM LABORATORIES  TORRENT PHARMA  PANACEA BIOTECH  WOCKHARDT LTD.  CADILA HEALTHCARE  



Today's Market

Of Sensex Touching New Highs, Takeaways from Acquisition of HPCL and Top Stocks in Action Today(Pre-Open)

BSE Sensex is on a roll. The index touched a record high of 35,798 yesterday. Considering a span of one year, the benchmark index has delivered a 32% return.

Related Views On News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA 5-YR ANALYSIS

COMPARE SHASUN PHARMA WITH

MARKET STATS